Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib + trastuzumab + mFOLFOX6 versus standard first-line therapy in HER2-positive metastatic colorectal cancer
2024-514180-25-00Phase 3Authorised
- Sponsor
- Seagen Inc.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of tucatinib, trastuzumab, cetuximab, bevacizumab and mFOLFOX6 in colorectal cancer (CRC) (2 arms), sponsored by Seagen Inc. Primary endpoint: Progression-free survival per BICR. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-514180-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514180-25-00.